Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

African Trypanosomiasis Therapeutics Pipeline Review 2016 Featuring Novartis AG, Sanofi & Scynexis - Research and Markets

Research and Markets
Posted on: 03 Oct 16

Research and Markets has announced the addition of the "African Trypanosomiasis - Pipeline Review, H2 2016" report to their offering.

'African Trypanosomiasis - Pipeline Review, H2 2016'; African Trypanosomiasis pipeline therapeutics constitutes close to 13 molecules. Out of which approximately 4 molecules are developed by Companies and remaining by the Universities Institutes.

African Trypanosomiasis African trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to humans through the bite of the tsetse fly. Symptoms include anxiety, drowsiness during the day, fever, headache, insomnia at night, mood changes, sleepiness (may be uncontrollable), sweating, swollen lymph nodes all over the body, swollen, red, painful nodule at site of fly bite and weakness. Treatment includes anti-protozoal agents.

The report 'African Trypanosomiasis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 3 and 4 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. African Trypanosomiasis Overview
  3. Therapeutics Development
  4. Pipeline Products for African Trypanosomiasis - Overview
  5. Pipeline Products for African Trypanosomiasis - Comparative Analysis
  6. African Trypanosomiasis - Therapeutics under Development by Companies
  7. African Trypanosomiasis - Therapeutics under Investigation by Universities/Institutes
  8. African Trypanosomiasis Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. African Trypanosomiasis - Products under Development by Companies
  13. African Trypanosomiasis - Products under Investigation by Universities/Institutes
  14. African Trypanosomiasis - Companies Involved in Therapeutics Development
  • Novartis AG
  • Sanofi
  • Scynexis, Inc.

For more information about this report visit http://www.researchandmarkets.com/research/xw38f7/african

View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006249/en/

Business Wire
www.businesswire.com

Last updated on: 03/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.